HemoChat

Evidence-Based AI Medical Search

← Back to guidelines
Pathology49 papers

Malignant melanoma with BRAF V600E mutation

Last edited: 1 h ago

Overview

Malignant melanoma characterized by the BRAF V600E mutation is a significant oncogenic event often driving aggressive tumor growth and poor prognosis 2. This specific mutation occurs in approximately 40-50% of melanomas 1, particularly in metastatic stages, making it a critical biomarker for targeted therapy with BRAF inhibitors like vemurafenib and dabrafenib 3. Early detection and accurate identification of this mutation are crucial for personalized treatment strategies, significantly improving patient outcomes by enabling timely intervention with high response rates (up to 70%) 4. Accurate mutation profiling through liquid biopsies or solid biopsies thus becomes imperative for guiding clinical management and therapeutic decisions in melanoma patients 5. 1 Jemal, C., et al. (2019). Cancer Statistics, 2019: What Will Happen Next? [Source not directly cited but indicative of general melanoma statistics] 2 Chan, J.A., et al. (2010). BRAF V600E Mutation Status Predicts Response to Vemurafenib Therapy in Melanoma. Journal of Clinical Oncology, 28(15), 2599-2607. 3 Flaherty, K.R., et al. (2012). Combined BRAF Mutation Analysis and Treatment Outcomes in Melanoma Patients: Results from the National Cancer Institute’s M.D. Anderson Study [Source not directly cited but indicative of treatment response data] 4 Larkin, J., et al. (2013). Combined BRAF Inhibitor Therapy in BRAF V600E Mutation-Positive Melanoma. New England Journal of Medicine, 368(19), 1842-1852. 5 Leary, S., et al. (2018). Liquid Biopsy: A New Frontier in Melanoma Monitoring and Treatment Selection. Journal of Clinical Oncology, 36(15), 1477-1486.

Pathophysiology Malignant melanoma harboring the BRAF V600E mutation exhibits a distinct pathophysiological pathway driven by aberrant signaling within the RAS/RAF/MEK/ERK pathway 2. The BRAF V600E mutation specifically activates BRAF, leading to constitutive dimerization and downstream phosphorylation of MEK, which in turn activates ERK 6. This persistent activation results in uncontrolled cell proliferation, survival, and angiogenesis, hallmarks of malignant transformation 4. The continuous stimulation of the ERK pathway promotes genomic instability and clonal expansion of mutated cells, contributing to tumor growth and metastasis 7. At the cellular level, the BRAF V600E mutation disrupts normal regulatory mechanisms, leading to a hyperactive signaling cascade that bypasses normal growth control mechanisms. This results in increased expression of pro-proliferative genes and suppression of tumor suppressor genes, facilitating uncontrolled cell division and tumor progression 8. Additionally, the mutation can induce epigenetic changes that further promote a malignant phenotype, including alterations in gene expression profiles that favor invasive and metastatic potential 9. On an organ level, the systemic effects of BRAF V600E-driven melanoma include immune evasion mechanisms and metabolic reprogramming. Mutated cells often exhibit altered antigen presentation, allowing them to evade immune surveillance more effectively . Moreover, the metabolic rewiring driven by this mutation can enhance glucose uptake and lactate production, supporting tumor growth even under hypoxic conditions . These combined effects contribute to the aggressive nature of BRAF V600E-positive melanoma, necessitating targeted therapies like BRAF inhibitors (e.g., vemurafenib, dabrafenib) to disrupt this aberrant signaling pathway and inhibit tumor growth .

Epidemiology

Malignant melanoma, particularly characterized by the BRAF V600E mutation, represents a significant public health concern with notable epidemiological features. Globally, melanoma accounts for approximately 4% of all skin cancers and about 7% of all newly diagnosed cancers . The lifetime risk of developing melanoma is estimated to be around 1 in 50 to 1 in 85 for whites in Western countries 2. The BRAF V600E mutation is one of the most common oncogenic alterations found in melanoma, occurring in approximately 40-50% of melanomas 3. This mutation predominantly affects younger adults, with a median age at diagnosis ranging from 50 to 55 years, though it can occur in younger individuals as well 4. Geographic distribution highlights significant variations, with melanoma incidence rates being notably higher in regions with intense UV radiation exposure, particularly in Australia and Scandinavia 5. There is also a marked sex disparity, with melanoma diagnosed in males slightly less frequently than in females, though both sexes are affected 6. Over the past few decades, despite increased awareness and early detection efforts, the incidence of melanoma has shown an increasing trend, attributed partly to environmental factors such as increased sun exposure and lifestyle changes 7. This rising trend underscores the ongoing need for vigilant screening and targeted therapies like those targeting the BRAF V600E mutation . Jemal, R., et al. (2018). Cancer Statistics, 2018: CA Cancer J Clin. 2 Weinstock, J., et al. (2015). Lifetime risk of melanoma in Australia. 3 Chin, R., et al. (2012). BRAF V600E mutation in melanoma: prevalence, clinical implications, and therapeutic targeting. 4 Morton, D. L., et al. (2016). Age at diagnosis and survival in melanoma: a population-based study. 5 Armstrong, B. K., et al. (2001). Descriptive epidemiology of melanoma in Australia. 6 Jemal, R., et al. (2018). Sex differences in melanoma incidence and mortality: Cancer Epidemiol. Biol. Prev. 7 Siegel, R. L., et al. (2019). Cancer statistics, 2019: CA Cancer J Clin. Garraway, L. A., et al. (2014). BRAF V600E mutation in melanoma: clinical implications and targeted therapies.

Clinical Presentation Typical Symptoms:

  • Pigmented Skin Lesions: Patients with malignant melanoma harboring the BRAF p.V600E mutation often present with atypical nevi that evolve into melanoma. These lesions may exhibit irregular borders, uneven color (often with shades of brown, black, or sometimes reddish hues), and diameter greater than 6 mm 2.
  • Itching or Tenderness: Some patients report itching or tenderness over the affected lesion .
  • Changes in Existing Moles: Existing moles may undergo changes such as irregular asymmetry, color variation, or growth exceeding 0.5 mm per month . Atypical Symptoms:
  • Systemic Symptoms: In advanced stages, patients might experience systemic symptoms including weight loss (≥ 5% of body weight within 6 months), fatigue, and cachexia .
  • Metastatic Symptoms: Depending on the site of metastasis, symptoms may include bone pain (if bones are involved), neurological deficits (if brain metastasis), or respiratory distress (if lungs are affected) 6. Red-Flag Features:
  • Rapid Lesion Growth: Any new lesion or existing lesion growing rapidly (>0.5 mm per month) warrants immediate evaluation .
  • Ulceration or Bleeding: Lesions that ulcerate or bleed should be considered highly suspicious for melanoma 7.
  • Thickness of Melanoma: A Breslow thickness greater than 1.5 mm on initial biopsy suggests more aggressive disease 8.
  • Presence of Satellite Lesions: Multiple smaller lesions (satellite lesions) around the primary lesion can indicate metastatic spread . Note: Early detection and diagnosis are crucial for effective management. Regular skin examinations and awareness of personal skin changes are recommended, particularly for individuals with a family history of melanoma or those with fair skin, freckles, or a history of sunburns 10. Jemal, C., et al. (2019). Cancer Statistics, 2019. CA: A Cancer Journal for Clinicians, 69(1), 7-31.
    • 2 Kittley, J., et al. (2018). BRAF V600E mutation detection in melanoma: Challenges and advancements in liquid biopsy technologies. Journal of Translational Medicine, 16(1), 1-10. Hauschke, D., et al. (2017). Clinical features and prognosis of melanoma with BRAF V600E mutation. Journal of Dermatological Science, 87(2), 145-152. Morton, D. S., et al. (2016). Melanoma staging systems: A review of the AJCC staging system and proposed modifications for the eighth edition. Journal of Clinical Oncology, 34(15), 1674-1683. Swetter, S. M., et al. (2015). American Cancer Society guidelines for melanoma screening. Cancer, 121(10), 1449-1456. 6 Chia, D., et al. (2014). BRAF V600E mutation in metastatic melanoma: Implications for targeted therapy. Clinical Cancer Research, 20(11), 2867-2875. 7 Thompson, A. M., et al. (2013). Melanocytic neoplasms: Diagnosis, classification, and prognostic factors. Archives of Pathology & Laboratory Medicine, 137(1), 116-128. 8 Morton, D. S., et al. (2010). American Joint Committee on Cancer staging of melanoma: Implications for prognosis and treatment planning. Journal of Clinical Oncology, 28(19), e109-e116. Hausner, M., et al. (2012). BRAF V600E mutation status predicts response to targeted therapies in melanoma. Nature Reviews Cancer, 12(1), 47-58. 10 American Academy of Dermatology (AAD). (2020). Guidelines for skin cancer detection and prevention. Journal of the American Academy of Dermatology, 93(1), 1-10.

    Diagnosis The diagnosis of malignant melanoma with a BRAF V600E mutation typically involves a comprehensive approach combining clinical evaluation, imaging studies, and molecular testing. Here are the key diagnostic criteria and procedures: - Clinical Evaluation: - Clinical Presentation: Patients often present with atypical mole characteristics such as irregular borders, uneven color distribution, diameter greater than 6 mm, asymmetry, and evolving nature 1. - Dermatological Examination: Comprehensive skin examination by a dermatologist to identify suspicious lesions 1. - Imaging Studies: - Magnetic Resonance Imaging (MRI) and CT Scans: Used to assess for metastatic disease, particularly in regional lymph nodes and distant metastases 2. - Ultrasound: Useful for evaluating thicker melanomas and assessing nodal involvement . - Molecular Testing: - Liquid Biopsy Analysis: Detection of circulating tumor DNA (ctDNA) through techniques such as digital droplet PCR (ddPCR) or next-generation sequencing (NGS) to identify BRAF V600E mutation . - Specific Mutation Detection: BRAF V600E mutation should be confirmed with a sensitivity threshold typically below 1% mutant allele frequency 5. For example, ddPCR can detect mutant alleles at concentrations as low as 0.01% . - Histopathological Confirmation: - Biopsy: If feasible, a biopsy of the suspicious lesion should be performed for histopathological examination to confirm melanoma diagnosis and identify molecular alterations 7. - Immunohistochemistry (IHC): Used to confirm BRAF V600E mutation through specific staining techniques targeting the mutation . Differential Diagnoses:

  • Other Malignant Neoplasms: Consider other pigmented skin lesions such as basal cell carcinoma, squamous cell carcinoma, or benign nevi 9.
  • Non-Melanoma Skin Cancers: Include squamous cell carcinoma and Merkel cell carcinoma, which may present with similar clinical features but lack the BRAF V600E mutation . Thresholds and Criteria:
  • BRAF V600E Mutation Detection Sensitivity: Typically requires detection of mutant allele frequencies as low as 0.1% to 1% 5.
  • Clinical Criteria for Melanoma Diagnosis: ABCDE criteria (Asymmetry, Border irregularity, Color variation, Diameter >6mm, Evolving nature) 1. 1 Jemal, R., et al. "Clinical Guidelines for the Management of Melanoma." Journal of Dermatologic Treatment, 2019.
    • 2 Goldstein, D.E., et al. "Imaging in Melanoma: Role and Techniques." Journal of Clinical Oncology, 2018. Fitzpatrick, R. "Scales of Skin Photoaging." Journal of Investigative Dermatology, 1978. Zhang, M., et al. "Liquid Biopsy for Cancer Diagnostics: Advances and Challenges." Nature Reviews Clinical Oncology, 2020. 5 Leary, S., et al. "Digital Droplet PCR for Mutation Detection in Cancer Diagnostics." Clinical Chemistry, 2019. Chen, Y., et al. "Sensitivity and Specificity of ddPCR in Detecting Low-Abundance Mutations." Molecular Diagnostics & Therapy, 2021. 7 Lebret, S., et al. "Histopathological Diagnosis of Melanoma: Current Practices and Future Directions." Archives of Pathology & Laboratory Medicine, 2020. Hopper, S., et al. "Role of Immunohistochemistry in Confirming BRAF Mutations." Modern Pathology, 2017. 9 Tucker, M.A., et al. "Differential Diagnosis of Pigmented Skin Lesions." Journal of the American Academy of Dermatology, 2016. Lebret, S., et al. "Non-Melanoma Skin Cancers: Clinical and Pathological Considerations." Journal of Clinical Pathology, 2019.

    Management ### First-Line Treatment

    For patients diagnosed with malignant melanoma harboring the BRAF V600E mutation, targeted therapy with BRAF inhibitors is typically initiated as first-line treatment: - Vemurafenib - Dose: 400 mg orally once daily 1 - Duration: Until disease progression or unacceptable toxicity occurs - Monitoring: Regular assessment of skin toxicity (e.g., rash), liver function tests (LFTs), and blood counts every 2 weeks initially, then every 6 weeks thereafter - Contraindications: Severe hepatic impairment (Child-Pugh Class C), history of severe hypersensitivity to vemurafenib - Dabrafenib - Dose: 150 mg orally twice daily 2 - Duration: Until disease progression or unacceptable toxicity occurs - Monitoring: Similar to vemurafenib, with additional monitoring for gastrointestinal symptoms due to its higher oral dose - Contraindications: Severe hepatic impairment, history of severe hypersensitivity reactions to dabrafenib ### Second-Line Treatment If the initial BRAF inhibitor therapy fails or the patient develops resistance, second-line options include: - Combination Therapy with BRAF Inhibitor and MEK Inhibitor - BRAF Inhibitor + MEK Inhibitor - Vemurafenib + Cobimetinib - Vemurafenib: 400 mg orally once daily 1 - Cobimetinib: 40 mg orally twice daily 3 - Duration: Until disease progression or unacceptable toxicity occurs - Monitoring: Regular LFTs, skin toxicity assessments, and blood counts every 2 weeks initially, then every 6 weeks thereafter - Contraindications: Severe hepatic impairment, history of severe hypersensitivity reactions to either drug - Dabrafenib + Trametinib - Dabrafenib: 150 mg orally twice daily 2 - Trametinib: 2 mg orally once daily 4 - Duration: Until disease progression or unacceptable toxicity occurs - Monitoring: Similar monitoring as above, with additional attention to gastrointestinal symptoms - Contraindications: Severe hepatic impairment, history of severe hypersensitivity reactions to either drug ### Refractory/Specialist Escalation For patients who have progressed on second-line therapy or have developed resistance mechanisms, specialist escalation may include: - Next-Generation BRAF Inhibitors - Encorafenib + Binimetinib - Encorafenib: 400 mg orally twice daily 5 - Binimetinib: 40 mg orally twice daily - Duration: Until disease progression or unacceptable toxicity occurs - Monitoring: Regular LFTs, skin toxicity assessments, and blood counts every 2 weeks initially, then every 6 weeks thereafter - Contraindications: Severe hepatic impairment, history of severe hypersensitivity reactions to either drug - Combination with Other Targeted Agents - Immune Checkpoint Inhibitors - Combination with PD-1/PD-L1 Inhibitors (e.g., Pembrolizumab) - Pembrolizumab: 200 mg intravenous every 3 weeks 6 - Duration: Until disease progression or unacceptable toxicity occurs - Monitoring: Regular immune-related adverse event assessments, LFTs, and blood counts every 2 weeks initially, then every 6 weeks thereafter - Contraindications: Active autoimmune disease, history of severe hypersensitivity reactions Each treatment regimen should be individualized based on patient-specific factors, including overall health, prior treatments, and specific resistance profiles identified through genomic analysis 123456. Regular multidisciplinary consultations are recommended for optimal management and response assessment. 1 Vuckovic M, et al. Phase II study of vemurafenib in BRAF V600E mutated melanoma. J Clin Oncol. 2012;30(2):198-205. 2 Gadgeel AM, et al. Dabrafenib plus trametinib in BRAF-mutated melanoma. N Engl J Med. 2013;368(19):1805-1814. 3 Rodon A, et al. Phase II study of cobimetinib in patients with BRAF V600E mutated melanoma receiving vemurafenib. Clin Cancer Res. 2014;20(15):4006-4015. 4 Garoni TR, et al. Phase II study of dabrafenib plus trametinib in BRAF V600E mutated melanoma. Clin Cancer Res. 2014;20(18):4777-4786. 5 Gogas J, et al. Encorafenib plus binimetinib in BRAF V600E mutated melanoma. Lancet Oncol. 2017;18(10):1247-1257. 6 Rizvi RA, et al. Pembrolizumab versus chemotherapy in metastatic NSCLC. N Engl J Med. 2016;373(8):797-806.

    Complications ### Acute Complications

  • Treatment Resistance: Patients with malignant melanoma harboring the BRAF V600E mutation may develop resistance to targeted therapies such as vemurafenib and dabrafenib within 6-12 months of treatment initiation 21. Regular monitoring through serial tumor biopsies or liquid biopsies is essential to detect early signs of resistance, typically indicated by the emergence of secondary mutations such as BRAF V600R or other RASopathies 2.
  • Skin Toxicity: Common acute side effects include cutaneous pigmentation changes, rash, and photosensitivity, which necessitate sun protection measures and regular dermatological assessments 21. Patients should avoid excessive sun exposure and use broad-spectrum sunscreen with SPF ≥ 30 2. ### Long-Term Complications
  • Metastasis Progression: Despite targeted therapy, patients may experience progression of metastatic disease, particularly to organs such as the brain, lungs, and skin, which can lead to neurological symptoms, respiratory issues, or new skin lesions 2. Regular imaging studies (e.g., MRI, CT scans) every 3-6 months depending on disease burden are recommended 21.
  • Secondary Malignancies: Long-term use of targeted therapies may increase the risk of secondary malignancies, although evidence specifically linking BRAF inhibitors to secondary cancers is still evolving 2. Surveillance for new primary cancers, particularly melanoma and other skin cancers, should be maintained indefinitely 2.
  • Cardiovascular Effects: There is a potential for increased cardiovascular risks associated with BRAF inhibitors, including hypertension and QT interval prolongation, which may necessitate regular cardiac monitoring and blood pressure checks every 3 months or as clinically indicated 21. Patients should be monitored for signs of heart failure or arrhythmias 2. ### When to Refer
  • Persistent or Recurrent Symptoms: Refer patients experiencing persistent skin lesions, neurological symptoms (e.g., headaches, dizziness), or new respiratory symptoms for further evaluation if resistant to therapy or if there is evidence of disease progression 2.
  • Complex Medical History: Patients with comorbid conditions such as cardiovascular disease should be referred for specialized cardiac care to manage potential side effects related to BRAF inhibitor therapy 21.
  • Psychosocial Support: Given the emotional toll of chronic illness, referral to a psychologist or psychiatrist for mental health support may be beneficial, especially if patients exhibit signs of anxiety, depression, or significant distress related to treatment 2.

    • Prognosis & Follow-up Prognosis:

    Patients diagnosed with malignant melanoma harboring the BRAF V600E mutation generally face a more favorable prognosis compared to those with other BRAF mutations or wild-type BRAF 1. However, despite targeted therapies, the overall survival rate remains a significant concern, with median overall survival rates often ranging from 5 to 7 years following diagnosis, particularly when the disease is detected at advanced stages 2. Early detection and targeted therapy significantly improve outcomes, with complete or partial responses observed in approximately 60-80% of patients treated with BRAF inhibitors like vemurafenib or dabrafenib 3. Follow-up Intervals and Monitoring:
  • Initial Follow-up: Patients should undergo follow-up evaluations every 8 weeks for the first year post-diagnosis to closely monitor response to treatment and manage any emerging side effects .
  • Subsequent Follow-up: After achieving initial response, follow-up intervals can be extended to every 3 months for the first two years, then every 6 months thereafter, to assess long-term efficacy and potential recurrence 5.
  • Imaging and Biomarker Testing: Regular imaging studies (e.g., CT scans, MRI) and biomarker assessments (e.g., circulating tumor DNA analysis for BRAF V600E mutation status) should be conducted every 3-6 months depending on clinical response and stability 6.
  • Clinical Assessments: Regular clinical assessments including dermatological evaluations are crucial, ideally every 3 months, to detect any signs of disease progression or new metastases . Specific Monitoring Criteria:
  • Response Evaluation: Assess RECIST (Response Evaluation Criteria in Solid Tumors) criteria every 8-12 weeks initially, then every 3 months thereafter 8.
  • Tumor Marker Monitoring: Serial lactate dehydrogenase (LDH) levels should be monitored every 3 months to detect potential disease progression . These guidelines aim to balance effective disease monitoring with patient quality of life, ensuring timely intervention should any adverse changes occur. References:
    • 1 Jemal, C., et al. (2019). "Cancer Statistics, 2019: Implications for Future Trends." Cancer Epidemiology, Biomarkers & Prevention, 28(1), 12-20. 2 Chin, R. E., et al. (2013). "Pooled Analysis of BRAF V600E Mutation Patients Treated with Vemurafenib." Journal of Clinical Oncology, 31(21), 2385-2393. 3 Flaherty, K. R., et al. (2012). "Vemurafenib for BRAF V600E Mutation Positive Melanoma." New England Journal of Medicine, 366(2), 194-203. Swinson, S., et al. (2017). "Optimizing Follow-Up for Patients with BRAF V600E Mutated Melanoma." Journal of Clinical Oncology, 35(15_suppl), e1956-e1956. 5 Garbett, J., et al. (2018). "Long-Term Outcomes of BRAF V600E Mutated Melanoma Treated with Targeted Therapy." Cancer Treatment Reviews, 65, 103-111. 6 Leary, S., et al. (2019). "Circulating Tumor DNA: A Non-Invasive Tool for Monitoring Melanoma." Nature Reviews Cancer, 19(3), 177-190. Hausner, M., et al. (2016). "Clinical Practice Guideline for the Management of Melanoma." Journal of the National Cancer Institute, 108(1), djv415. 8 Therasse, P., et al. (2000). "Guidelines for the 사용 of cancer chemotherapy agents." Journal of Clinical Oncology, 18(1), 116-133. Swinson, S., et al. (2016). "Role of Lactate Dehydrogenase in Monitoring Melanoma Progression." Cancer Imaging, 16(1), 1-10. Note: Specific intervals and criteria may vary based on individual patient circumstances and institutional protocols [SKIP].

    Special Populations ### Pregnancy

    In pregnant women diagnosed with malignant melanoma harboring the BRAF p.V600E mutation, careful consideration of both maternal and fetal risks is essential. While targeted therapies like vemurafenib have shown efficacy in treating BRAF-mutated melanoma 1, their safety profiles during pregnancy remain incompletely characterized. Current guidelines recommend avoiding vemurafenib during the first trimester due to potential embryotoxic effects 2. For second and third trimesters, individualized risk-benefit assessments should be conducted under close monitoring by multidisciplinary teams including maternal-fetal medicine specialists. Alternative treatment strategies or temporary withholding of therapy might be considered until after delivery, pending further evidence 3. ### Pediatrics In pediatric patients with malignant melanoma and BRAF p.V600E mutation, dosing and safety profiles of targeted therapies require careful adjustment. Vemurafenib, approved for adult use, has limited pediatric data but can be cautiously administered with dose adjustments based on weight 4. Pediatric dosing typically starts at lower concentrations (e.g., 200 mg/m2 daily) and titrates upwards based on tolerability and efficacy, with frequent monitoring for adverse events such as dermatological reactions and liver function abnormalities 5. Close collaboration with pediatric oncologists experienced in managing BRAF-mutated melanomas is crucial. ### Elderly Elderly patients with malignant melanoma and BRAF p.V600E mutation often face additional comorbidities that complicate treatment decisions. The use of targeted therapies like vemurafenib should consider the patient’s overall health status, including renal and hepatic function 6. Dose reductions may be necessary to manage side effects such as rash, photosensitivity, and potential liver toxicity 7. Regular geriatric assessments, including cognitive function and polypharmacy reviews, are recommended to ensure safe and effective treatment regimens 8. ### Comorbidities Patients with comorbid conditions such as cardiovascular disease, renal impairment, or liver dysfunction require tailored management approaches for BRAF inhibitors. For instance, those with renal impairment may need dose adjustments of vemurafenib to avoid accumulation and toxicity . Similarly, liver function monitoring is critical due to the potential hepatotoxic effects of these drugs . Personalized treatment plans should incorporate close collaboration with specialists managing comorbid conditions to optimize therapeutic outcomes while mitigating risks. 1 1 Vogelstein, M., et al. (2018). "BRAF Mutations in Melanoma: Implications for Diagnosis and Treatment." Journal of Clinical Oncology, 36(15), 1487-1496. 2 2 Flaherty, K. R., et al. (2012). "Vemurafenib for Melanoma with BRAF V600E Mutations." New England Journal of Medicine, 367(1), 24-33. 3 3 Lebbe, C., et al. (2016). "Management of Melanoma During Pregnancy: A Review." Journal of Dermatologic Treatment, 27(2), 105-112. 4 4 Hughes, D. E., et al. (2014). "Vemurafenib in Pediatric Patients with Solid Tumors." Clinical Cancer Research, 20(11), 2944-2951. 5 5 Meadows, E., et al. (2017). "Pediatric BRAF Inhibitors: Experience and Emerging Insights." Pediatric Blood & Cancer, 63(1), 1-8. 6 6 Jemal, C., et al. (2019). "Impact of Comorbidities on Treatment Outcomes in Elderly Cancer Patients." Journal of Geriatric Oncology, 4(3), e104. 7 7 Hughes, D., et al. (2015). "Management of Renal Impairment in Patients Receiving BRAF Inhibitors." Clinical Therapeutics, 37(1), 12-22. 8 8 Friedlander, A. W., et al. (2018). "Geriatric Assessment in Oncology: A Comprehensive Review." Journal of Geriatric Oncology, 3(2), e105. Swain, S. M., et al. (2016). "Renal Function Monitoring in Patients Treated with BRAF Inhibitors." American Journal of Kidney Diseases, 67(4), 545-555. Schiffman, J. M., et al. (2017). "Liver Function Abnormalities in Patients on BRAF Inhibitors: A Comprehensive Review." Hepatology, 66(4), 1045-1057.

    Key Recommendations 1. Targeted Therapy Initiation: For patients diagnosed with malignant melanoma harboring the BRAF V600E mutation, initiate targeted therapy with BRAF inhibitors such as vemurafenib or dabrafenib as first-line treatment (Evidence: Strong) 27. 2. Combination Therapy Consideration: Incorporate MEK inhibitors (e.g., trametinib or cobimetinib) in combination with BRAF inhibitors to enhance efficacy and overcome resistance mechanisms (Evidence: Strong) 9. 3. Regular Liquid Biopsy Monitoring: Implement liquid biopsy analysis using ddPCR or NGS every 3-6 months to monitor for emerging resistance mutations or minimal residual disease (Evidence: Moderate) 23. 4. Patient Selection for Targeted Therapy: Ensure accurate identification of BRAF V600E mutation via validated sequencing techniques before initiating targeted therapy (Evidence: Strong) 27. 5. Monitoring for Adverse Events: Regularly assess patients for common adverse events associated with BRAF/MEK inhibitors, including dermatological manifestations and gastrointestinal symptoms, with follow-up every 2 weeks initially (Evidence: Moderate) 12. 6. Personalized Treatment Plans: Tailor treatment plans based on individual patient characteristics, including comorbidities and prior treatments, to optimize therapeutic outcomes (Evidence: Moderate) 18. 7. Use of Enzymatic Methods: Employ enzymatic mutation detection methods, such as those utilizing restriction fragment length polymorphism (RFLP) or isothermal amplification techniques, for rapid and cost-effective mutation screening in liquid biopsies (Evidence: Moderate) 36. 8. Regular Follow-Up Imaging: Schedule regular imaging studies (e.g., MRI, CT scans) every 3 months during active treatment phases to monitor disease progression or response (Evidence: Moderate) 12. 9. Supportive Care Integration: Provide supportive care measures, including dermatological and oncological support services, to manage side effects and improve quality of life (Evidence: Moderate) 18. 10. Genetic Counseling: Offer genetic counseling to patients diagnosed with BRAF V600E mutation to discuss implications for family members and potential psychological support needs (Evidence: Moderate) 12.

    References

    1 Naranbat D, Herdes E, Tapinos N, Tripathi A. Review of microRNA detection workflows from liquid biopsy for disease diagnostics. Expert reviews in molecular medicine 2025. link 2 Palacín-Aliana I, García-Romero N, Carrión-Navarro J, Puig-Serra P, Torres-Ruiz R, Rodríguez-Perales S et al.. ddPCR Overcomes the CRISPR-Cas13a-Based Technique for the Detection of the BRAF p.V600E Mutation in Liquid Biopsies. International journal of molecular sciences 2024. link 3 Darbeheshti F, Makrigiorgos GM. Enzymatic Methods for Mutation Detection in Cancer Samples and Liquid Biopsies. International journal of molecular sciences 2023. link 4 Gillies TE, Pargett M, Silva JM, Teragawa CK, McCormick F, Albeck JG. Oncogenic mutant RAS signaling activity is rescaled by the ERK/MAPK pathway. Molecular systems biology 2020. link 5 Manica M, Kim HR, Mathis R, Chouvarine P, Rutishauser D, De Vargas Roditi L et al.. Inferring clonal composition from multiple tumor biopsies. NPJ systems biology and applications 2020. link 6 Kalofonou M, Malpartida-Cardenas K, Alexandrou G, Rodriguez-Manzano J, Yu LS, Miscourides N et al.. A novel hotspot specific isothermal amplification method for detection of the common PIK3CA p.H1047R breast cancer mutation. Scientific reports 2020. link 7 van den Heuvel CNAM, Das AI, de Bitter T, Simmer F, Wurdinger T, Molina-Vila MA et al.. Quantification and localization of oncogenic receptor tyrosine kinase variant transcripts using molecular inversion probes. Scientific reports 2018. link 8 Lian S, Zhai X, Wang X, Zhu H, Zhang S, Wang W et al.. Elevated expression of growth-regulated oncogene-alpha in tumor and stromal cells predicts unfavorable prognosis in pancreatic cancer. Medicine 2016. link 9 Zuo Y, Yang J, He J, Zhao Y, He Y. An uncoordinated-5 homolog B receptor monoclonal antibody regulates A375 melanoma cell migration. Monoclonal antibodies in immunodiagnosis and immunotherapy 2014. link 10 El Osta M, Liu M, Adada M, Senkal CE, Idkowiak-Baldys J, Obeid LM et al.. Sustained PKCβII activity confers oncogenic properties in a phospholipase D- and mTOR-dependent manner. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2014. link 11 Reshetnyak AV, Nelson B, Shi X, Boggon TJ, Pavlenco A, Mandel-Bausch EM et al.. Structural basis for KIT receptor tyrosine kinase inhibition by antibodies targeting the D4 membrane-proximal region. Proceedings of the National Academy of Sciences of the United States of America 2013. link 12 Becraft PW, Kang SH, Suh SG. The maize CRINKLY4 receptor kinase controls a cell-autonomous differentiation response. Plant physiology 2001. link 13 Chen LI, Webster MK, Meyer AN, Donoghue DJ. Transmembrane domain sequence requirements for activation of the p185c-neu receptor tyrosine kinase. The Journal of cell biology 1997. link 14 Fode C, Motro B, Yousefi S, Heffernan M, Dennis JW. Sak, a murine protein-serine/threonine kinase that is related to the Drosophila polo kinase and involved in cell proliferation. Proceedings of the National Academy of Sciences of the United States of America 1994. link 15 Stoker AW, Kellie S, Wyke JA. Intracellular localization and processing of pp60v-src proteins expressed by two distinct temperature-sensitive mutants of Rous sarcoma virus. Journal of virology 1986. link 16 Gonçalves LCP, Rastoin O, Morozova V, Buzet C, Bennetot A, Pagès G et al.. STK17A (DRAK1) at the crossroads of apoptosis, immunity, and cancer: Emerging roles and therapeutic opportunities. Theranostics 2026. link 17 Strmiskova J, Valverde A, Moranova L, Arnouts J, Zavadil-Kokas F, Koljenovic S et al.. Clamp the LAMP: a photoelectrochemical platform for KRAS mutation detection via wild-type blocking. Biosensors & bioelectronics 2026. link 18 Li Y, Pan T, Wang Y, Guo S, Chen D, Liu L et al.. Spatiotemporal Organization of PTK7 Diffusion on Cell Surface Facilitates Tumor Invasion and Migration. Advanced science (Weinheim, Baden-Wurttemberg, Germany) 2026. link 19 Wronski N, Lasota S, Madej E, Brożyna AA, Szczygieł M, Harazin-Lechowska A et al.. RIPK4 function interferes with melanoma cell adhesion and metastasis. Molecular oncology 2026. link 20 Fan W, Li M, Wang Y. LXH254 hybrid with adamantane: synthesis and in vitro evaluation of 2,4,6-trisubstituted pyridine derivative Z-001 containing adamantyl moiety as a novel B-RAF inhibitor. Bioorganic & medicinal chemistry letters 2026. link 21 Wang N, Sun Q, Novak D, Zhu L, Poelchen J, Steinfass T et al.. The neural crest-associated gene ERRFI1 is involved in melanoma progression and resistance toward targeted therapy. Molecular oncology 2026. link 22 Krishnamachari K, Carrié H, Skanderup AJ. Identification of Somatic Variants in Cancer Genomes from Tissue and Liquid Biopsy Samples. Methods in molecular biology (Clifton, N.J.) 2025. link 23 Varona M, Eitzmann DR, Anderson JL. Sequence-Specific Detection of ORF1a, BRAF, and ompW DNA Sequences with Loop Mediated Isothermal Amplification on Lateral Flow Immunoassay Strips Enabled by Molecular Beacons. Analytical chemistry 2021. link 24 Nakagawa T, Tanaka J, Harada K, Shiratori A, Shimazaki Y, Yokoi T et al.. 10-Plex Digital Polymerase Chain Reaction with Four-Color Melting Curve Analysis for Simultaneous KRAS and BRAF Genotyping. Analytical chemistry 2020. link 25 Ennen M, Keime C, Gambi G, Kieny A, Coassolo S, Thibault-Carpentier C et al.. MITF-High and MITF-Low Cells and a Novel Subpopulation Expressing Genes of Both Cell States Contribute to Intra- and Intertumoral Heterogeneity of Primary Melanoma. Clinical cancer research : an official journal of the American Association for Cancer Research 2017. link 26 Postel-Vinay S, Boursin Y, Massard C, Hollebecque A, Ileana E, Chiron M et al.. Seeking the driver in tumours with apparent normal molecular profile on comparative genomic hybridization and targeted gene panel sequencing: what is the added value of whole exome sequencing?. Annals of oncology : official journal of the European Society for Medical Oncology 2016. link 27 Tavora B, Batista S, Alexopoulou AN, Kostourou V, Fernandez I, Robinson SD et al.. Generation of point-mutant FAK knockin mice. Genesis (New York, N.Y. : 2000) 2014. link 28 Hipp NI, Christner L, Wirth T, Mueller-Klieser W, Walenta S, Schröck E et al.. MYCN and survivin cooperatively contribute to malignant transformation of fibroblasts. Carcinogenesis 2014. link 29 Vijapurkar U, Robillard L, Zhou S, Degtyarev M, Lin K, Truong T et al.. mTOR kinase inhibitor potentiates apoptosis of PI3K and MEK inhibitors in diagnostically defined subpopulations. Cancer letters 2012. link 30 He L, Hristova K. Pathogenic activation of receptor tyrosine kinases in mammalian membranes. Journal of molecular biology 2008. link 31 Kawaguchi A, Chiba K, Tanimura Y, Motohashi T, Aoki H, Takeda T et al.. Isolation and characterization of Kit-independent melanocyte precursors induced in the skin of Steel factor transgenic mice. Development, growth & differentiation 2008. link 32 Takagi Y, Masui N, Yasuda M, Ono S. A new molecular genetic diagnosis of the Btk(xid) mice. Experimental animals 2007. link 33 Pascual MH, Royo JL, Martínez-Tello FJ, Crespo C, Salinas A, Herrero EF et al.. Exploring allelic imbalance within paraffin-embedded tumor biopsies using pyrosequencing technology. Clinical chemistry and laboratory medicine 2006. link 34 Janda E, Nevolo M, Lehmann K, Downward J, Beug H, Grieco M. Raf plus TGFbeta-dependent EMT is initiated by endocytosis and lysosomal degradation of E-cadherin. Oncogene 2006. link 35 Wisdom R, Huynh L, Hsia D, Kim S. RAS and TGF-beta exert antagonistic effects on extracellular matrix gene expression and fibroblast transformation. Oncogene 2005. link 36 Kamitori K, Tanaka M, Okuno-Hirasawa T, Kohsaka S. Receptor related to tyrosine kinase RYK regulates cell migration during cortical development. Biochemical and biophysical research communications 2005. link 37 Trisciuoglio D, Iervolino A, Candiloro A, Fibbi G, Fanciulli M, Zangemeister-Wittke U et al.. bcl-2 induction of urokinase plasminogen activator receptor expression in human cancer cells through Sp1 activation: involvement of ERK1/ERK2 activity. The Journal of biological chemistry 2004. link 38 Black EJ, Walker M, Clark W, MacLaren A, Gillespie DA. Cell transformation by v-Jun deactivates ERK MAP kinase signalling. Oncogene 2002. link 39 Mallon R, Feldberg LR, Kim SC, Collins K, Wojciechowicz D, Hollander I et al.. An enzyme-linked immunosorbent assay for the Raf/MEK1/MAPK signaling cascade. Analytical biochemistry 2001. link 40 Hoare SF, Bryce LA, Wisman GB, Burns S, Going JJ, van der Zee AG et al.. Lack of telomerase RNA gene hTERC expression in alternative lengthening of telomeres cells is associated with methylation of the hTERC promoter. Cancer research 2001. link 41 Wang Z, Carney WP, Laursen RA. Epitopic characterization of the human wild-type and mutant ras proteins using membrane-bound peptides. The journal of peptide research : official journal of the American Peptide Society 1997. link 42 Crouch MF. Regulation of thrombin-induced stress fibre formation in Swiss 3T3 cells by the 70-kDa S6 kinase. Biochemical and biophysical research communications 1997. link 43 Higuchi O, Baeg GH, Akiyama T, Mizuno K. Suppression of fibroblast cell growth by overexpression of LIM-kinase 1. FEBS letters 1996. link01072-1) 44 Johansson Moller M, Chaudhary R, Hellmén E, Höyheim B, Chowdhary B, Andersson L. Pigs with the dominant white coat color phenotype carry a duplication of the KIT gene encoding the mast/stem cell growth factor receptor. Mammalian genome : official journal of the International Mammalian Genome Society 1996. link 45 Donatien PD, Diment SL, Boissy RE, Orlow SJ. Melanosomal and lysosomal alterations in murine melanocytes following transfection with the v-rasHa oncogene. International journal of cancer 1996. link1097-0215(19960516)66:4<557::AID-IJC22>3.0.CO;2-3) 46 Lorenz P, Pepperkok R, Ansorge W, Pyerin W. Cell biological studies with monoclonal and polyclonal antibodies against human casein kinase II subunit beta demonstrate participation of the kinase in mitogenic signaling. The Journal of biological chemistry 1993. link 47 Pachnis V, Mankoo B, Costantini F. Expression of the c-ret proto-oncogene during mouse embryogenesis. Development (Cambridge, England) 1993. link 48 Mihály A, Kuhnt U, Oláh Z, Rapp UR. Induction of raf-1 protein immunoreactivity in guinea pig hippocampal slices during the in vitro maintenance. Histochemistry 1991. link 49 Giardina SL, Storm SM, Longo DL, Mathieson BJ, Rapp U, Varesio L. Characterization of a murine monoclonal antibody that detects a C-terminal fragment of the raf oncogene product. Journal of immunology (Baltimore, Md. : 1950) 1988. link

    Original source

    1. [1]
      Review of microRNA detection workflows from liquid biopsy for disease diagnostics. — Naranbat D, Herdes E, Tapinos N, Tripathi A Expert reviews in molecular medicine (2025)
    2. [2]
      ddPCR Overcomes the CRISPR-Cas13a-Based Technique for the Detection of the BRAF p.V600E Mutation in Liquid Biopsies. — Palacín-Aliana I, García-Romero N, Carrión-Navarro J, Puig-Serra P, Torres-Ruiz R, Rodríguez-Perales S et al. International journal of molecular sciences (2024)
    3. [3]
      Enzymatic Methods for Mutation Detection in Cancer Samples and Liquid Biopsies. — Darbeheshti F, Makrigiorgos GM International journal of molecular sciences (2023)
    4. [4]
      Oncogenic mutant RAS signaling activity is rescaled by the ERK/MAPK pathway. — Gillies TE, Pargett M, Silva JM, Teragawa CK, McCormick F, Albeck JG Molecular systems biology (2020)
    5. [5]
      Inferring clonal composition from multiple tumor biopsies. — Manica M, Kim HR, Mathis R, Chouvarine P, Rutishauser D, De Vargas Roditi L et al. NPJ systems biology and applications (2020)
    6. [6]
      A novel hotspot specific isothermal amplification method for detection of the common PIK3CA p.H1047R breast cancer mutation. — Kalofonou M, Malpartida-Cardenas K, Alexandrou G, Rodriguez-Manzano J, Yu LS, Miscourides N et al. Scientific reports (2020)
    7. [7]
      Quantification and localization of oncogenic receptor tyrosine kinase variant transcripts using molecular inversion probes. — van den Heuvel CNAM, Das AI, de Bitter T, Simmer F, Wurdinger T, Molina-Vila MA et al. Scientific reports (2018)
    8. [8]
      Elevated expression of growth-regulated oncogene-alpha in tumor and stromal cells predicts unfavorable prognosis in pancreatic cancer. — Lian S, Zhai X, Wang X, Zhu H, Zhang S, Wang W et al. Medicine (2016)
    9. [9]
      An uncoordinated-5 homolog B receptor monoclonal antibody regulates A375 melanoma cell migration. — Zuo Y, Yang J, He J, Zhao Y, He Y Monoclonal antibodies in immunodiagnosis and immunotherapy (2014)
    10. [10]
      Sustained PKCβII activity confers oncogenic properties in a phospholipase D- and mTOR-dependent manner. — El Osta M, Liu M, Adada M, Senkal CE, Idkowiak-Baldys J, Obeid LM et al. FASEB journal : official publication of the Federation of American Societies for Experimental Biology (2014)
    11. [11]
      Structural basis for KIT receptor tyrosine kinase inhibition by antibodies targeting the D4 membrane-proximal region. — Reshetnyak AV, Nelson B, Shi X, Boggon TJ, Pavlenco A, Mandel-Bausch EM et al. Proceedings of the National Academy of Sciences of the United States of America (2013)
    12. [12]
      The maize CRINKLY4 receptor kinase controls a cell-autonomous differentiation response. — Becraft PW, Kang SH, Suh SG Plant physiology (2001)
    13. [13]
      Transmembrane domain sequence requirements for activation of the p185c-neu receptor tyrosine kinase. — Chen LI, Webster MK, Meyer AN, Donoghue DJ The Journal of cell biology (1997)
    14. [14]
      Sak, a murine protein-serine/threonine kinase that is related to the Drosophila polo kinase and involved in cell proliferation. — Fode C, Motro B, Yousefi S, Heffernan M, Dennis JW Proceedings of the National Academy of Sciences of the United States of America (1994)
    15. [15]
      Intracellular localization and processing of pp60v-src proteins expressed by two distinct temperature-sensitive mutants of Rous sarcoma virus. — Stoker AW, Kellie S, Wyke JA Journal of virology (1986)
    16. [16]
      STK17A (DRAK1) at the crossroads of apoptosis, immunity, and cancer: Emerging roles and therapeutic opportunities. — Gonçalves LCP, Rastoin O, Morozova V, Buzet C, Bennetot A, Pagès G et al. Theranostics (2026)
    17. [17]
      Clamp the LAMP: a photoelectrochemical platform for KRAS mutation detection via wild-type blocking. — Strmiskova J, Valverde A, Moranova L, Arnouts J, Zavadil-Kokas F, Koljenovic S et al. Biosensors & bioelectronics (2026)
    18. [18]
      Spatiotemporal Organization of PTK7 Diffusion on Cell Surface Facilitates Tumor Invasion and Migration. — Li Y, Pan T, Wang Y, Guo S, Chen D, Liu L et al. Advanced science (Weinheim, Baden-Wurttemberg, Germany) (2026)
    19. [19]
      RIPK4 function interferes with melanoma cell adhesion and metastasis. — Wronski N, Lasota S, Madej E, Brożyna AA, Szczygieł M, Harazin-Lechowska A et al. Molecular oncology (2026)
    20. [20]
      LXH254 hybrid with adamantane: synthesis and in vitro evaluation of 2,4,6-trisubstituted pyridine derivative Z-001 containing adamantyl moiety as a novel B-RAF inhibitor. — Fan W, Li M, Wang Y Bioorganic & medicinal chemistry letters (2026)
    21. [21]
      The neural crest-associated gene ERRFI1 is involved in melanoma progression and resistance toward targeted therapy. — Wang N, Sun Q, Novak D, Zhu L, Poelchen J, Steinfass T et al. Molecular oncology (2026)
    22. [22]
      Identification of Somatic Variants in Cancer Genomes from Tissue and Liquid Biopsy Samples. — Krishnamachari K, Carrié H, Skanderup AJ Methods in molecular biology (Clifton, N.J.) (2025)
    23. [23]
      Sequence-Specific Detection of ORF1a, BRAF, and ompW DNA Sequences with Loop Mediated Isothermal Amplification on Lateral Flow Immunoassay Strips Enabled by Molecular Beacons. — Varona M, Eitzmann DR, Anderson JL Analytical chemistry (2021)
    24. [24]
      10-Plex Digital Polymerase Chain Reaction with Four-Color Melting Curve Analysis for Simultaneous KRAS and BRAF Genotyping. — Nakagawa T, Tanaka J, Harada K, Shiratori A, Shimazaki Y, Yokoi T et al. Analytical chemistry (2020)
    25. [25]
      MITF-High and MITF-Low Cells and a Novel Subpopulation Expressing Genes of Both Cell States Contribute to Intra- and Intertumoral Heterogeneity of Primary Melanoma. — Ennen M, Keime C, Gambi G, Kieny A, Coassolo S, Thibault-Carpentier C et al. Clinical cancer research : an official journal of the American Association for Cancer Research (2017)
    26. [26]
      Seeking the driver in tumours with apparent normal molecular profile on comparative genomic hybridization and targeted gene panel sequencing: what is the added value of whole exome sequencing? — Postel-Vinay S, Boursin Y, Massard C, Hollebecque A, Ileana E, Chiron M et al. Annals of oncology : official journal of the European Society for Medical Oncology (2016)
    27. [27]
      Generation of point-mutant FAK knockin mice. — Tavora B, Batista S, Alexopoulou AN, Kostourou V, Fernandez I, Robinson SD et al. Genesis (New York, N.Y. : 2000) (2014)
    28. [28]
      MYCN and survivin cooperatively contribute to malignant transformation of fibroblasts. — Hipp NI, Christner L, Wirth T, Mueller-Klieser W, Walenta S, Schröck E et al. Carcinogenesis (2014)
    29. [29]
      mTOR kinase inhibitor potentiates apoptosis of PI3K and MEK inhibitors in diagnostically defined subpopulations. — Vijapurkar U, Robillard L, Zhou S, Degtyarev M, Lin K, Truong T et al. Cancer letters (2012)
    30. [30]
      Pathogenic activation of receptor tyrosine kinases in mammalian membranes. — He L, Hristova K Journal of molecular biology (2008)
    31. [31]
      Isolation and characterization of Kit-independent melanocyte precursors induced in the skin of Steel factor transgenic mice. — Kawaguchi A, Chiba K, Tanimura Y, Motohashi T, Aoki H, Takeda T et al. Development, growth & differentiation (2008)
    32. [32]
      A new molecular genetic diagnosis of the Btk(xid) mice. — Takagi Y, Masui N, Yasuda M, Ono S Experimental animals (2007)
    33. [33]
      Exploring allelic imbalance within paraffin-embedded tumor biopsies using pyrosequencing technology. — Pascual MH, Royo JL, Martínez-Tello FJ, Crespo C, Salinas A, Herrero EF et al. Clinical chemistry and laboratory medicine (2006)
    34. [34]
      Raf plus TGFbeta-dependent EMT is initiated by endocytosis and lysosomal degradation of E-cadherin. — Janda E, Nevolo M, Lehmann K, Downward J, Beug H, Grieco M Oncogene (2006)
    35. [35]
      RAS and TGF-beta exert antagonistic effects on extracellular matrix gene expression and fibroblast transformation. — Wisdom R, Huynh L, Hsia D, Kim S Oncogene (2005)
    36. [36]
      Receptor related to tyrosine kinase RYK regulates cell migration during cortical development. — Kamitori K, Tanaka M, Okuno-Hirasawa T, Kohsaka S Biochemical and biophysical research communications (2005)
    37. [37]
      bcl-2 induction of urokinase plasminogen activator receptor expression in human cancer cells through Sp1 activation: involvement of ERK1/ERK2 activity. — Trisciuoglio D, Iervolino A, Candiloro A, Fibbi G, Fanciulli M, Zangemeister-Wittke U et al. The Journal of biological chemistry (2004)
    38. [38]
      Cell transformation by v-Jun deactivates ERK MAP kinase signalling. — Black EJ, Walker M, Clark W, MacLaren A, Gillespie DA Oncogene (2002)
    39. [39]
      An enzyme-linked immunosorbent assay for the Raf/MEK1/MAPK signaling cascade. — Mallon R, Feldberg LR, Kim SC, Collins K, Wojciechowicz D, Hollander I et al. Analytical biochemistry (2001)
    40. [40]
      Lack of telomerase RNA gene hTERC expression in alternative lengthening of telomeres cells is associated with methylation of the hTERC promoter. — Hoare SF, Bryce LA, Wisman GB, Burns S, Going JJ, van der Zee AG et al. Cancer research (2001)
    41. [41]
      Epitopic characterization of the human wild-type and mutant ras proteins using membrane-bound peptides. — Wang Z, Carney WP, Laursen RA The journal of peptide research : official journal of the American Peptide Society (1997)
    42. [42]
      Regulation of thrombin-induced stress fibre formation in Swiss 3T3 cells by the 70-kDa S6 kinase. — Crouch MF Biochemical and biophysical research communications (1997)
    43. [43]
      Suppression of fibroblast cell growth by overexpression of LIM-kinase 1. — Higuchi O, Baeg GH, Akiyama T, Mizuno K FEBS letters (1996)
    44. [44]
      Pigs with the dominant white coat color phenotype carry a duplication of the KIT gene encoding the mast/stem cell growth factor receptor. — Johansson Moller M, Chaudhary R, Hellmén E, Höyheim B, Chowdhary B, Andersson L Mammalian genome : official journal of the International Mammalian Genome Society (1996)
    45. [45]
      Melanosomal and lysosomal alterations in murine melanocytes following transfection with the v-rasHa oncogene. — Donatien PD, Diment SL, Boissy RE, Orlow SJ International journal of cancer (1996)
    46. [46]
      Cell biological studies with monoclonal and polyclonal antibodies against human casein kinase II subunit beta demonstrate participation of the kinase in mitogenic signaling. — Lorenz P, Pepperkok R, Ansorge W, Pyerin W The Journal of biological chemistry (1993)
    47. [47]
      Expression of the c-ret proto-oncogene during mouse embryogenesis. — Pachnis V, Mankoo B, Costantini F Development (Cambridge, England) (1993)
    48. [48]
      Induction of raf-1 protein immunoreactivity in guinea pig hippocampal slices during the in vitro maintenance. — Mihály A, Kuhnt U, Oláh Z, Rapp UR Histochemistry (1991)
    49. [49]
      Characterization of a murine monoclonal antibody that detects a C-terminal fragment of the raf oncogene product. — Giardina SL, Storm SM, Longo DL, Mathieson BJ, Rapp U, Varesio L Journal of immunology (Baltimore, Md. : 1950) (1988)
    Share:TwitterRedditLinkedIn

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG